114 related articles for article (PubMed ID: 26440564)
21. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer.
Martoni AA; Di Fabio F; Pinto C; Castellucci P; Pini S; Ceccarelli C; Cuicchi D; Iacopino B; Di Tullio P; Giaquinta S; Tardio L; Lombardi R; Fanti S; Cola B
Ann Oncol; 2011 Mar; 22(3):650-656. PubMed ID: 20847032
[TBL] [Abstract][Full Text] [Related]
22. Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis?
Jaffe TA; Neville AM; Bashir MR; Uronis HE; Thacker JM
Colorectal Dis; 2013 Nov; 15(11):e654-8. PubMed ID: 23910050
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation.
Perez RO; Habr-Gama A; São Julião GP; Proscurshim I; Ono CR; Lynn P; Bailão Aguilar P; Nahas SC; Gama-Rodrigues J; Buchpiguel CA
Colorectal Dis; 2013 Jun; 15(6):674-82. PubMed ID: 23374979
[TBL] [Abstract][Full Text] [Related]
24. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
[TBL] [Abstract][Full Text] [Related]
25. Proposal of a new 18F-FDG PET/CT predictor of response in rectal cancer treated by neoadjuvant chemoradiation therapy and comparison with PERCIST criteria.
Maffione AM; Ferretti A; Chondrogiannis S; Rampin L; Marzola MC; Grassetto G; Capirci C; Colletti PM; Rubello D
Clin Nucl Med; 2013 Oct; 38(10):795-7. PubMed ID: 24107808
[TBL] [Abstract][Full Text] [Related]
26. The value of 18F-FDG PET/CT for assessing the response to neoadjuvant therapy in locally advanced rectal cancer.
Murcia Duréndez MJ; Frutos Esteban L; Luján J; Frutos MD; Valero G; Navarro Fernández JL; Mohamed Salem L; Ruiz Merino G; Claver Valderas MA
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):91-7. PubMed ID: 23081822
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer.
Cascini GL; Avallone A; Delrio P; Guida C; Tatangelo F; Marone P; Aloj L; De Martinis F; Comella P; Parisi V; Lastoria S
J Nucl Med; 2006 Aug; 47(8):1241-8. PubMed ID: 16883000
[TBL] [Abstract][Full Text] [Related]
28. ¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.
Calvo FA; Sole CV; de la Mata D; Cabezón L; Gómez-Espí M; Alvarez E; Madariaga P; Carreras JL
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):657-67. PubMed ID: 23436067
[TBL] [Abstract][Full Text] [Related]
29. Voxel-based dual-time 18F-FDG parametric imaging for rectal cancer: differentiation of residual tumor from postchemoradiotherapy changes.
Choi H; Yoon HJ; Kim TS; Oh JH; Kim DY; Kim SK
Nucl Med Commun; 2013 Dec; 34(12):1166-73. PubMed ID: 24128896
[TBL] [Abstract][Full Text] [Related]
30. (18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
Metser U; Rashidi F; Moshonov H; Wong R; Knox J; Guindi M; Darling G
Ann Nucl Med; 2014 May; 28(4):295-303. PubMed ID: 24474598
[TBL] [Abstract][Full Text] [Related]
31. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F
Oncology; 2013; 84(4):191-9. PubMed ID: 23328390
[TBL] [Abstract][Full Text] [Related]
32. [(18)F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma.
Withofs N; Martinive P; Vanderick J; Bletard N; Scagnol I; Mievis F; Giacomelli F; Coucke P; Delvenne P; Cataldo D; Gambhir SS; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):654-62. PubMed ID: 26490751
[TBL] [Abstract][Full Text] [Related]
33. The use of PET in assessing tumor response after neoadjuvant chemoradiation for rectal cancer.
Mak D; Joon DL; Chao M; Wada M; Joon ML; See A; Feigen M; Jenkins P; Mercuri A; McNamara J; Poon A; Khoo V
Radiother Oncol; 2010 Nov; 97(2):205-11. PubMed ID: 20598390
[TBL] [Abstract][Full Text] [Related]
34. Metabolic response of rectal cancer assessed by 18-FDG PET following chemoradiotherapy is prognostic for patient outcome.
Yeung JM; Kalff V; Hicks RJ; Drummond E; Link E; Taouk Y; Michael M; Ngan S; Lynch AC; Heriot AG
Dis Colon Rectum; 2011 May; 54(5):518-25. PubMed ID: 21471751
[TBL] [Abstract][Full Text] [Related]
35. Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer.
van den Bogaard J; Janssen MH; Janssens G; Buijsen J; Reniers B; Lambin P; Lammering G; Ollers MC
Radiother Oncol; 2011 May; 99(2):137-41. PubMed ID: 21571386
[TBL] [Abstract][Full Text] [Related]
36. Value of FDG-PET/CT Volumetry After Chemoradiotherapy in Rectal Cancer.
Okuno T; Kawai K; Koyama K; Takahashi M; Ishihara S; Momose T; Morikawa T; Fukayama M; Watanabe T
Dis Colon Rectum; 2018 Mar; 61(3):320-327. PubMed ID: 29360680
[TBL] [Abstract][Full Text] [Related]
37. Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology.
Fischer MA; Vrugt B; Alkadhi H; Hahnloser D; Hany TF; Veit-Haibach P
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1563-73. PubMed ID: 24760269
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of 18F-FDG PET/CT on survival in locally advanced rectal cancer after neoadjuvant chemoradiation.
Niccoli Asabella A; Simone M; Ballini A; Altini C; Ferrari C; Lavelli V; De Luca R; Inchingolo F; Rubini G
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8227-8236. PubMed ID: 30556862
[TBL] [Abstract][Full Text] [Related]
39. Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer?
Li YL; Wu LM; Chen XX; Delproposto Z; Hu JN; Xu JR
J Dig Dis; 2014 Oct; 15(10):525-37. PubMed ID: 25060294
[TBL] [Abstract][Full Text] [Related]
40. (18)F-FDG PET bio-metabolic monitoring of neoadjuvant therapy effects in rectal cancer: focus on nodal disease characteristics.
Calvo FA; Cabezón L; González C; Soria A; de la Mata D; Gómez-Espí M; García-Alfonso P; Alvarez E; Carreras JL
Radiother Oncol; 2010 Nov; 97(2):212-6. PubMed ID: 20970865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
